Charles River Labs (CRL) AI Stock Analysis

Company Guidance

The company raised its full-year 2026 outlook, now expecting reported revenue to decline 2.5%–3.5% while organic revenue should be flat to up 1% (a 150‑bp improvement versus prior guidance); by segment management guides DSA to low single‑digit organic growth, Manufacturing to low‑ to mid‑single‑digit organic growth, and RMS to a low‑ to mid‑single‑digit organic decline. Full‑year non‑GAAP operating margin is forecast to expand ~120–150 bps, with a clear line of sight to at least a 500‑bp improvement in H2 versus H1 (about half of the H2 improvement from completed portfolio actions and lower NHP sourcing costs, ~150 bps from lower corporate costs, remainder from operational contributions), and non‑GAAP EPS is raised to $11.15–$11.45 (≈8%–11% YoY). Additional metrics: Q3 reported revenue is expected to decline ~4%–6% while Q3 organic revenue should grow ~1%–3%, Q3 non‑GAAP EPS is guided to $2.90–$3.00 (≈20% YoY) with roughly +200 bps sequential margin improvement, full‑year non‑GAAP tax rate 23%–24% (≈+100 bps; ~$0.20 EPS headwind), net interest expense $103M–$108M, free cash flow raised to $400M–$420M, average diluted shares ~48.5M, net leverage ~2.5x, and $300M of share repurchases year‑to‑date (including $100M in Q2) under a $1B authorization.